Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478682 | 1.00 | MAPK1 (0.48) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 | |
| SCHEMBL1430201 | 0.77 | KCNN4 (0.50) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 | |
| SCHEMBL462758 | 0.77 | KCNN4 (0.50) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 | |
| SCHEMBL3034923 | 0.76 | MAPK1 (0.44) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL7899276 | 0.75 | KCNN4 (0.48) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 | |
| SCHEMBL3685988 | 0.75 | TAAR1 (0.45) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 | |
| SCHEMBL10918770 | 0.74 | KIF11 (0.40) | ALDH1A1CYP3A4 | |
| SCHEMBL3844071 | 0.74 | MAPK1 (0.52) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 | |
| SCHEMBL664301 | 0.74 | MAPK1 (0.52) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 | |
| SCHEMBL42639 | 0.74 | MAPK1 (0.67) | MAPK1KCNN4TAAR1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008100618-A2 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20190343819-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2019-11-14 | — | — | US | disclosed |
| US-9044469-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8835488-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8742052-B2 | Polyurea compound | NUPLEX RESINS B.V. (NL) | 2014-06-03 | — | — | US | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-1846469-B1 | A POLYUREA COMPOUND | NUPLEX RESINS BV (NL) | 2014-04-30 | — | — | EP | disclosed |
| US-20130331408-A1 | Opioid Receptor Ligands and Methods of Using and Making Same | TREVENA, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080139755-A1 | Polyurea Compound | ALLNEX NETHERLANDS B.V. (NL) | 2008-06-12 | — | — | US | disclosed |
| EP-1846469-A1 | A POLYUREA COMPOUND | Nuplex Resins B.V. (NL) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006075000-A1 | A POLYUREA COMPOUND | NUPLEX RESINS B.V. (NL) | 2006-07-20 | — | — | WO | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6229020-B1 | REACTING N-SUCCINIMIDYL AND P-NITROPHENYL CINNAMATE DERIVATIVES WITH PHYSIOLOGICALLY ACTIVE SUBSTANCE SUCH AS AN AMINO ACID; PROTECTING AMINO OR HYDROXY GROUPS FOR ANALYSIS OF BIOLOGICAL REACTIONS BY IRRADIATION WITH LIGHT | LABORATORY OF MOLECULAR BIOPHOTONICS (JP) | 2001-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343819-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | MAPK1 4197/4885KCNN4 632/4885TAAR1 58/4885 |
| US-20130331408-A1 | Opioid Receptor Ligands and Methods of Using and Making Same | OPRL1, OPRK1, OPRM1 | MAPK1 4197/4885KCNN4 632/4885TAAR1 58/4885 |
| US-20100286202-A1 | New Compounds | REN, PCSK9, FURIN | MAPK1 3756/4885KCNN4 3182/4885TAAR1 4096/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | MAPK1 1807/4885KCNN4 3138/4885TAAR1 3251/4885 |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | OPRL1, OPRK1, OPRM1 | MAPK1 4197/4885KCNN4 632/4885TAAR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.